...
首页> 外文期刊>European respiratory review >Cell therapy for lung disease
【24h】

Cell therapy for lung disease

机译:肺部疾病的细胞疗法

获取原文

摘要

Besides cancer and cardiovascular diseases; lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions no effective and curative treatment options are available. Cell therapies offer a novel therapeutic approach due to their inherent anti-inflammatory and anti-fibrotic properties. Mesenchymal stem/stromal cells (MSC) are the most studied cell product. Numerous preclinical studies demonstrate an improvement of disease-associated parameters after MSC administration in several lung disorders; including chronic obstructive pulmonary disease; acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Furthermore; results from clinical studies using MSCs for the treatment of various lung diseases indicate that MSC treatment in these patients is safe. In this review we summarise the results of preclinical and clinical studies that indicate that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless; further investigations are required.
机译:除了癌症和心血管疾病;肺部疾病是全世界发病和死亡的主要原因。对于许多疾病,没有有效的治疗选择。细胞疗法由于其固有的抗炎和抗纤维化特性而提供了一种新颖的治疗方法。间充质干/基质细胞(MSC)是研究最多的细胞产物。许多临床前研究表明,在多种肺部疾病中使用MSC后,疾病相关参数的改善。包括慢性阻塞性肺疾病;急性呼吸窘迫综合征和特发性肺纤维化。此外;使用MSC治疗各种肺部疾病的临床研究结果表明,在这些患者中进行MSC治疗是安全的。在这篇综述中,我们总结了临床前和临床研究的结果,这些结果表明,MSC是治疗肺部疾病的一种有前途的治疗方法。尽管如此;需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号